New data presented at the 14th International Congress of Parkinson’s Disease and Movement Disorders in Buenos Aires, Argentina, (June 13-17, 2010) showed that Neupro (rotigotine transdermal system) provided significantly greater improvement in early morning motor symptoms and sleep quality, compared with placebo, and as measured by the Unified Parkinson’s Disease Rating Scale and the Parkinson’s Disease Sleep Scale.
The latest [removed]data[/removed] come from an analysis from the RECOVER study—a multicenter, multinational, double-blind, placebo-controlled study designed to assess the effects of rotigotine in controlling early morning motor function and nonmotor symptoms that affect the everyday lives of people with Parkinson’s disease.
"Sleeping without being restless, uncomfortable or immobile during the night may be just as important to people with Parkinson’s disease, as being able to move around during the day," said Professor Claudia Trenkwalder from the Paracelsus-Elena Hospital, Kassel, Germany. "Findings from the RECOVER study showed that rotigotine was an effective treatment option for patients with Parkinson’s disease having beneficial effects on both motor and non-motor symptoms."
